Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV

Patricia A. Sirois, Grace Montepiedra, Suad Kapetanovic, Paige L. Williams, Deborah A. Pearson, Kathleen Malee, Patricia A. Garvie, Betsy L. Kammerer, Sharon L. Nichols, Molly L. Nozyce, Mark Mintz, Wendy G. Mitchell, James Oleske

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)403-412
Number of pages10
JournalJournal of Developmental and Behavioral Pediatrics
Volume30
Issue number5
DOIs
StatePublished - Oct 1 2009

Fingerprint

Attention Deficit Disorder with Hyperactivity
HIV
Growth
Weights and Measures
Prescriptions
Therapeutics
Population
Linear Models
Observational Studies
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Developmental and Educational Psychology
  • Medicine(all)
  • Pediatrics, Perinatology, and Child Health

Cite this

Sirois, Patricia A. ; Montepiedra, Grace ; Kapetanovic, Suad ; Williams, Paige L. ; Pearson, Deborah A. ; Malee, Kathleen ; Garvie, Patricia A. ; Kammerer, Betsy L. ; Nichols, Sharon L. ; Nozyce, Molly L. ; Mintz, Mark ; Mitchell, Wendy G. ; Oleske, James. / Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. In: Journal of Developmental and Behavioral Pediatrics. 2009 ; Vol. 30, No. 5. pp. 403-412.
@article{c4cea09dbcbd45e28a83c364835ff3b1,
title = "Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV",
abstract = "Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.",
author = "Sirois, {Patricia A.} and Grace Montepiedra and Suad Kapetanovic and Williams, {Paige L.} and Pearson, {Deborah A.} and Kathleen Malee and Garvie, {Patricia A.} and Kammerer, {Betsy L.} and Nichols, {Sharon L.} and Nozyce, {Molly L.} and Mark Mintz and Mitchell, {Wendy G.} and James Oleske",
year = "2009",
month = "10",
day = "1",
doi = "https://doi.org/10.1097/DBP.0b013e3181ba0cf6",
language = "English (US)",
volume = "30",
pages = "403--412",
journal = "Journal of Developmental and Behavioral Pediatrics",
issn = "0196-206X",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "5",

}

Sirois, PA, Montepiedra, G, Kapetanovic, S, Williams, PL, Pearson, DA, Malee, K, Garvie, PA, Kammerer, BL, Nichols, SL, Nozyce, ML, Mintz, M, Mitchell, WG & Oleske, J 2009, 'Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV', Journal of Developmental and Behavioral Pediatrics, vol. 30, no. 5, pp. 403-412. https://doi.org/10.1097/DBP.0b013e3181ba0cf6

Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. / Sirois, Patricia A.; Montepiedra, Grace; Kapetanovic, Suad; Williams, Paige L.; Pearson, Deborah A.; Malee, Kathleen; Garvie, Patricia A.; Kammerer, Betsy L.; Nichols, Sharon L.; Nozyce, Molly L.; Mintz, Mark; Mitchell, Wendy G.; Oleske, James.

In: Journal of Developmental and Behavioral Pediatrics, Vol. 30, No. 5, 01.10.2009, p. 403-412.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV

AU - Sirois, Patricia A.

AU - Montepiedra, Grace

AU - Kapetanovic, Suad

AU - Williams, Paige L.

AU - Pearson, Deborah A.

AU - Malee, Kathleen

AU - Garvie, Patricia A.

AU - Kammerer, Betsy L.

AU - Nichols, Sharon L.

AU - Nozyce, Molly L.

AU - Mintz, Mark

AU - Mitchell, Wendy G.

AU - Oleske, James

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.

AB - Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=74049163645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049163645&partnerID=8YFLogxK

U2 - https://doi.org/10.1097/DBP.0b013e3181ba0cf6

DO - https://doi.org/10.1097/DBP.0b013e3181ba0cf6

M3 - Article

C2 - 19827220

VL - 30

SP - 403

EP - 412

JO - Journal of Developmental and Behavioral Pediatrics

JF - Journal of Developmental and Behavioral Pediatrics

SN - 0196-206X

IS - 5

ER -